Project deliverable Open Access

SIMCor. Deliverable 10.1: In-silico trial impact assessment framework (ECRIN, M12)

Aydin, Burç; Ohmann, Christian


Dublin Core Export

<?xml version='1.0' encoding='utf-8'?>
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Aydin, Burç</dc:creator>
  <dc:creator>Ohmann, Christian</dc:creator>
  <dc:date>2021-12-17</dc:date>
  <dc:description>The objective of this deliverable is to define and develop a framework for estimating the impact of in-silico
methods and technologies on clinical and preclinical trials, laying the basis for the assessment of
broader effects on patient safety, animal welfare and industry workflow. In the introductory part a
status view on this area is given. The document starts with basic terminology and definitions related
to in-silico approaches. Thereafter, existing standards, guidelines and frameworks relevant for in-silico
trials are referenced. Examples and use cases of published in-silico trials are presented as well as
existing tools to support in-silico trials described. The introductory part of the deliverable closes with
a selection of projects and programs dedicated to in-silico approaches and relevant for SIMCor.
The approach for executing an in-silico trial in SIMCor will be based on the methodology provided by
Bodner and Kaul (Proceedings of the ASME 2021 Verification and Validation Symposium,
V001T02A0012021) for in-silico clinical trials for medical devices. This framework heavily relies on
ideas already developed for model verification, validation, and uncertainty quantification. The process
starts with the computational model, which is developed upstream of the in-silico trial. The next step
is to establish baseline credibility evidence with the goal that the model is ready to use for the in-silico
trial. After this step, clinical trial planning starts with developing the in-silico trial protocol. Thereafter,
the in-silico trial is designed as follows: a virtual cohort following the specifications of the human
cohort is generated and a final model validation will be performed using human data. If the model is
adequate the model predictions to the target population can be performed and the clinical endpoints
can be evaluated. An important aspect in applying in-silico trials is the transfer from engineering
outputs to clinical endpoints. To support this process, transfer functions based upon available data
will be considered in SIMCor.</dc:description>
  <dc:description>SIMCor (In-Silico testing and validation of Cardiovascular IMplantable devices) has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101017578.</dc:description>
  <dc:identifier>https://zenodo.org/record/6353628</dc:identifier>
  <dc:identifier>10.5281/zenodo.6353628</dc:identifier>
  <dc:identifier>oai:zenodo.org:6353628</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/grantAgreement/EC/Horizon 2020 Framework Programme - Research and Innovation action/101017578/</dc:relation>
  <dc:relation>doi:10.5281/zenodo.6353627</dc:relation>
  <dc:relation>url:https://zenodo.org/communities/simcor</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>https://creativecommons.org/licenses/by/4.0/legalcode</dc:rights>
  <dc:title>SIMCor. Deliverable 10.1: In-silico trial impact assessment framework (ECRIN, M12)</dc:title>
  <dc:type>info:eu-repo/semantics/report</dc:type>
  <dc:type>publication-deliverable</dc:type>
</oai_dc:dc>
87
79
views
downloads
All versions This version
Views 8787
Downloads 7979
Data volume 96.9 MB96.9 MB
Unique views 7979
Unique downloads 6161

Share

Cite as